 |
Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation for Early Onset LAL Deficiency from the U.S. Food and Drug Administration
May 20, 2013
|
26.6 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical
company developing therapeutic products for rare diseases, today
announced that the U.S. Food and Drug Administration (FDA) granted
Breakthrough Therapy designation to sebelipase alfa for the treatm...
|
|
Synageva BioPharma™ Joins the International MPS Network in Support of MPS Awareness Day 2013
May 15, 2013
|
26.6 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical
company developing therapeutic products for rare diseases, joins the
International MPS Network and others around the world in observing MPS
Awareness Day 2013. During MPS Awareness day, patient orga...
|
|
Synageva BioPharma™ Announces One Year of Treatment Data with Sebelipase Alfa in Late Onset LAL Deficiency
May 9, 2013
|
26.3 KB |
| |
-Sebelipase alfa effects sustained and treatment generally well
tolerated-
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical
company developing therapeutic products for rare diseases, today
reported 12-month results f...
|
|
Synageva BioPharma™ Reports First Quarter 2013 Financial Results
May 7, 2013
|
29.7 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical
company developing therapeutic products for rare diseases, today
reported first quarter 2013 financial results and provided other general
business updates.
First Quarter 201...
|
|
Late Onset LAL Deficiency (CESD) Literature Review Published in the Journal of Hepatology
Mar 26, 2013
|
25.9 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. (Synageva) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
diseases, announced the publication of an article by Bernstein et al
entitled, "Cholesteryl Ester Storage Disease: Review of the Findi...
|
|
Synageva BioPharma™ Reports 2012 Full Year Financial Results
Mar 11, 2013
|
33.8 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
disorders, today reported 2012 full year financial results and provided
2013 financial guidance. Synageva's management team will hos...
|
|
Synageva BioPharma™ to Host 2012 Fourth Quarter and Full Year Financial Results Conference Call on March 11
Mar 1, 2013
|
23.8 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. (Synageva) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
diseases, will report 2012 fourth quarter and full year financial
results after the NASDAQ Market closes on Monday, March 11, 2013.
...
|
|
Synageva BioPharma™ Joins NORD, EURORDIS, and The Global Genes Project in Support of Rare Disease Day 2013
Feb 28, 2013
|
26.8 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. (Synageva) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
diseases, joins the National Organization for Rare Disorders (NORD), the
European Organisation for Rare Diseases (EURORDIS), The Globa...
|
|
Synageva BioPharma™ to Present at the Cowen and Company 33rd Annual Health Care Conference
Feb 26, 2013
|
23.7 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
disorders, today announced its presentation at the upcoming Cowen and
Company 33rd Annual Health Care Conference.
...
|
|
Synageva BioPharma™ Initiates Dosing in Phase 3 Trial of Sebelipase Alfa in Children and Adults with Late Onset LAL Deficiency
Feb 11, 2013
|
25.5 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. (Synageva) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
diseases, today announced that the first patient initiated treatment in
the ARISE trial (Acid Lipase Replacement
Investigatin...
|
|
Synageva BioPharma™ to Present at the Leerink Swann Global Healthcare Conference 2013
Feb 6, 2013
|
23.8 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
disorders, today announced its presentation at the upcoming Leerink
Swann Global Healthcare Conference 2013.
...
|
|
Hepatology Publishes 12-Week Phase I/II Extension Study Data of Sebelipase Alfa in Adults with Late Onset LAL Deficiency
Feb 4, 2013
|
25.9 KB |
| |
- Sebelipase alfa improves markers of liver damage and dyslipidemia
associated with LAL Deficiency-
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. (Synageva) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
dis...
|
|
Synageva BioPharma™ Highlights Data Presentations at the 9th Annual Lysosomal Disease Network (LDN) WORLD Symposium
Jan 30, 2013
|
27.3 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. (Synageva) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
diseases, today announced presentations at the upcoming LDN WORLD
Symposium being held February 13-15 in Orlando, Florida. During an o...
|
|
Synageva BioPharma Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
Jan 9, 2013
|
26.3 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
disorders, today announced the closing of a $118 million underwritten
public offering of 2,472,500 shares of common stock, including...
|
|
Synageva BioPharma Announces Pricing of Public Offering of Common Stock
Jan 3, 2013
|
22.2 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a clinical
stage biopharmaceutical company developing therapeutic products for rare
disorders, today announced the pricing of its previously announced
underwritten public offering of common stock consisting of 2,150,000
...
|
|
Synageva BioPharma Announces $80 Million Proposed Public Offering of Common Stock
Jan 3, 2013
|
22.7 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a clinical
stage biopharmaceutical company developing therapeutic products for rare
disorders, today announced that it has commenced a $80 million
underwritten public offering of shares of its common stock. In
connec...
|
|
Synageva BioPharma™ to Present at the 31st Annual J.P. Morgan Healthcare Conference
Dec 19, 2012
|
24.3 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
disorders, announced today its presentation at the upcoming J.P. Morgan
Healthcare conference being held in San Francisco, CA.
...
|
|
Synageva BioPharma™ to Present at Upcoming Investor Conferences
Nov 19, 2012
|
24.5 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
disorders, today announced that Mark Goldberg, M.D., Senior Vice
President, Medical and Regulatory Affairs, will present at the Pipe...
|
|
Synageva BioPharma™ Announces Six-Month Data from Extension Study of SBC-102 (sebelipase alfa) in Late Onset LAL Deficiency at the AASLD Annual Meeting
Nov 10, 2012
|
27.7 KB |
| |
-Sebelipase alfa continues to correct a broad range of abnormalities
associated with late onset LAL D-
-Sebelipase alfa well-tolerated at six months and every other week
dosing-
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. ("Synageva") (NASDA...
|
|
Synageva BioPharma™ to Present at Upcoming Investor Conferences
Nov 7, 2012
|
24.2 KB |
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--
Synageva
BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
disorders, today announced that Sanj K. Patel, President and Chief
Executive Officer, will present at the Jefferies 2012 Global Heal...
|
|
|
